Emerging treatments

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. Stewart AK et al. N Engl J Med. 2014 Dec 6. [Epub ahead of print]. Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, inmultiple myeloma patients. Carmon L et al. Br J Haematol. 2014 Dec 11. doi: 10.1111/bjh.13245. [Epub ahead of print]. The potential role of PD0332991 (Palbociclib) in the…

Details

Biology and genetics

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. Gomez-Bougie P et al. Cancer Biol Ther. 2014 Dec 17:0. [Epub ahead of print]. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Nijhof IS et al. Haematologica. 2014 Dec 15. pii: haematol.2014.117531. [Epub ahead of print]. Doxorubicin Overcomes Resistance…

Details

General

The Role Of P2X Receptors In Bone Biology. Jorgensen NR et al. Curr Med Chem. 2014 Dec 14. [Epub ahead of print]. A joined role of canopy and reversal cells in bone remodeling – Lessons from glucocorticoid-induced osteoporosis. Jensen PR et al. Bone. 2014 Dec 10. pii: S8756-3282(14)00456-6. doi: 10.1016/j.bone.2014.12.004. [Epub ahead of print]. Multiple myeloma and chronic leukaemias in 2014: Improved…

Details

Complications of myeloma and its treatments

Bortezomib-induced acute pancreatitis: Case report and review of the literature. Talamo G et al. J Oncol Pharm Pract. 2014 Dec 15. pii: 1078155214563813. [Epub ahead of print]. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital. Teh BW et al. Support Care Cancer. 2014 Dec…

Details

Biology and genetics

Ex Vivo-expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients. Szmania S et al. J Immunother. 2014 Nov 20. [Epub ahead of print]. Establishment of a Murine Graft-versus-Myeloma Model Using Allogeneic Stem Cell Transplantation. Binsfeld M et al. PLoS One. 2014 Nov 21;9(11):e113764. doi: 10.1371/journal.pone.0113764. eCollection 2014. Exploration for the multi-effect of cardamom in’s resistance to multiple myeloma. Zhihua…

Details

Diagnostic tests and prognostic indicators

Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. Mathis S et al. Cytometry B Clin Cytom. 2014 Nov 17. doi: 10.1002/cyto.b.21200. [Epub ahead of print]. Clinical Course and Prognosis of Non-Secretory Multiple Myeloma. Chawla SS et al. Eur J Haematol. 2014 Nov 10. doi: 10.1111/ejh.12478. [Epub ahead of print]. The prognostic value…

Details

Related conditions

Plasma cell leukemia. Ravinet A et al. Bull Cancer. 2014 Nov 1;101(11):1048-1058. A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia. Kalff A et al. Haematologica. 2014 Nov 7. pii: haematol.2014.111385. [Epub ahead of print]. Solitary extramedullary plasmocytoma of the thyroid: a case report and histological approach to plasma cells infiltrate in the thyroid gland. Wilmars MM et…

Details

Emerging treatments

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Tolcher AW et al. Cancer Chemother Pharmacol. 2014 Nov 25. [Epub ahead of print]. Panobinostat: a review of trial results and future prospects in multiple myeloma. Libby EN et al. Expert Rev Hematol. 2014 Nov 20:1-10. [Epub ahead of print].…

Details